Pluristem Therapeutics Inc. (NASDAQ:PSTI) Expected to Announce Earnings of -$0.80 Per Share

Wall Street analysts expect that Pluristem Therapeutics Inc. (NASDAQ:PSTI) will post ($0.80) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Pluristem Therapeutics’ earnings. Pluristem Therapeutics also reported earnings per share of ($0.80) during the same quarter last year. The company is expected to announce its next earnings report on Thursday, November 14th.

According to Zacks, analysts expect that Pluristem Therapeutics will report full-year earnings of ($2.49) per share for the current financial year, with EPS estimates ranging from ($2.90) to ($2.08). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.80) per share. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that follow Pluristem Therapeutics.

PSTI has been the topic of several recent analyst reports. ValuEngine lowered shares of Pluristem Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. LADENBURG THALM/SH SH initiated coverage on shares of Pluristem Therapeutics in a research note on Monday, July 22nd. They set a “buy” rating on the stock. Finally, Zacks Investment Research upgraded shares of Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 10th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Pluristem Therapeutics has a consensus rating of “Buy” and a consensus price target of $27.50.

PSTI stock traded down $0.03 during midday trading on Wednesday, hitting $3.66. The company’s stock had a trading volume of 14,300 shares, compared to its average volume of 53,691. The stock has a market capitalization of $56.91 million, a P/E ratio of -1.46 and a beta of 1.05. The company’s fifty day moving average price is $3.88 and its 200 day moving average price is $2.05. Pluristem Therapeutics has a twelve month low of $3.24 and a twelve month high of $12.20.

Institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC boosted its holdings in shares of Pluristem Therapeutics by 28.1% during the 2nd quarter. Jane Street Group LLC now owns 153,322 shares of the biotechnology company’s stock worth $95,000 after buying an additional 33,630 shares during the period. Verition Fund Management LLC bought a new stake in shares of Pluristem Therapeutics during the 2nd quarter worth about $231,000. United Capital Financial Advisers LLC boosted its holdings in shares of Pluristem Therapeutics by 37.8% during the 2nd quarter. United Capital Financial Advisers LLC now owns 85,733 shares of the biotechnology company’s stock worth $53,000 after buying an additional 23,533 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Pluristem Therapeutics by 107.3% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,882,401 shares of the biotechnology company’s stock worth $1,168,000 after buying an additional 974,306 shares during the period. Finally, ARK Investment Management LLC boosted its holdings in shares of Pluristem Therapeutics by 35.9% during the 2nd quarter. ARK Investment Management LLC now owns 5,156,645 shares of the biotechnology company’s stock worth $32,007,000 after buying an additional 1,363,396 shares during the period. Institutional investors own 94.39% of the company’s stock.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

Featured Article: How to calculate the annual rate of depreciation

Get a free copy of the Zacks research report on Pluristem Therapeutics (PSTI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.